Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations.

Autor: Kaparou M; University Hospitals Birmingham NHS Foundation Trust, London, UK., Rudzki Z; University Hospitals Birmingham NHS Foundation Trust, London, UK., Giles H; University Hospitals Birmingham NHS Foundation Trust, London, UK., Murthy V; University Hospitals Birmingham NHS Foundation Trust, London, UK., Srinath S; University Hospitals Birmingham NHS Foundation Trust, London, UK., Lloyd R; University Hospitals Birmingham NHS Foundation Trust, London, UK., Ahmed MZ; University Hospitals Birmingham NHS Foundation Trust, London, UK., Salhan B; University Hospitals Birmingham NHS Foundation Trust, London, UK., Chauhan S; University Hospitals Birmingham NHS Foundation Trust, London, UK., Kishore B; University Hospitals Birmingham NHS Foundation Trust, London, UK., Lovell R; University Hospitals Birmingham NHS Foundation Trust, London, UK., Horgan C; University Hospitals Birmingham NHS Foundation Trust, London, UK., Paneesha S; University Hospitals Birmingham NHS Foundation Trust, London, UK., Xenou E; University Hospitals Birmingham NHS Foundation Trust, London, UK., Lokare A; University Hospitals Birmingham NHS Foundation Trust, London, UK., Ewing J; University Hospitals Birmingham NHS Foundation Trust, London, UK., Dassanayake H; University Hospitals Birmingham NHS Foundation Trust, London, UK., Nikolousis E; University Hospitals Birmingham NHS Foundation Trust, London, UK., Kanellopoulos A; University Hospitals Birmingham NHS Foundation Trust, London, UK.
Jazyk: angličtina
Zdroj: Case reports in hematology [Case Rep Hematol] 2021 Jan 21; Vol. 2021, pp. 8843063. Date of Electronic Publication: 2021 Jan 21 (Print Publication: 2021).
DOI: 10.1155/2021/8843063
Abstrakt: The present study describes a patient aged 70 with very high-risk AML who successfully received a nonmyeloablative matched unrelated donor allograft shortly following SARS-CoV-2 infection, which manifested with mild cough, interstitial abnormalities on chest CT, and pancytopenia with profound bone marrow biopsy histological alterations. In parallel, our study provides bone marrow biopsy data in a series of contemporary patients with serious haematological diseases who had a bone marrow biopsy performed within two weeks of PCR confirmation of SARS-CoV-2 infection. This study is notable because there are no published data describing the bone marrow biopsy changes observed in patients with haematological malignancies and SARS-CoV-2 infection. Finally, it is suggested that nonmyeloablative hematopoietic stem cell transplantation for very high-risk haematological malignancies can be successfully performed following recovery from SARS-CoV-2 infection.
Competing Interests: The authors declare no conflicts of interest were associated with this study.
(Copyright © 2021 Maria Kaparou et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje